Применение комбинированного гормонального контрацептива с дроспиреноном в условиях реальной клинической практики

Abstract

Objective. To analyze patient satisfaction and adherence to contraception with Delsia® (30 μg ethinylestradiol and 3 mg drospirenone). Patients and methods. This prospective observational study included 193 women from 12 Russian cities who used a combined oral hormonal contraceptive drug Delsia®. Results. No pregnancies were recorded in women taking Delsia® during the study. When included in the study, 34.2% of women had heavy menstrual bleeding and 39.9% of them had painful menstrual periods. By the end of the sixth month of using Delsia®, these rates decreased to 1.04% (p < 0.001) and 2.07% (p < 0.05), respectively. The percentage of patients who reported adverse reactions after 3 months of using Delsia® was 7.37% and it decreased to 3.83% by the sixth month. The mean BMI at the first visit was 22.75 ± 3.50 kg/m2 and 22.56 ± 3.29 kg/m2 by the end of the study (p < 0.05). Upon completion of the study, 99.47% of women were satisfied with the convenience of using Delsia® at 4–5 points on a Likert scale, 98.94% – with affordability, 97.88% – with tolerability, 99.47% – with skin and hair condition, 97.36% – with overall well-being, and 97.88% – with libido level. Conclusion. The data obtained allow us to highly evaluate the effect of the combined oral contraceptive drug Delsia® on the overall well-being of the observed patients and their satisfaction with therapy, which may ensure high adherence to this method of contraception. Key words: drospirenone, combined oral contraceptives, non-contraceptive benefits, adverse reactions